STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

about

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q54959839

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@en

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@nl

type

Item

label

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@en

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@nl

prefLabel

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@en

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@nl

P1476

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

@en

P2093

Aki Furusawa

http://www.w3.org/2001/XMLSchema#string

Arnob Banerjee

http://www.w3.org/2001/XMLSchema#string

Curt I Civin

http://www.w3.org/2001/XMLSchema#string

Haley M Simpson

http://www.w3.org/2001/XMLSchema#string

Kavitha Sadashivaiah

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of STAT5A and STAT5B target genes in human T cells

Therapeutic options in peripheral T cell lymphoma

Janus kinase deregulation in leukemia and lymphoma

Somatic STAT3 mutations in large granular lymphocytic leukemia

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

P304

16792-16806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24698

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29682185

http://www.w3.org/2001/XMLSchema#string

P932

5908286

http://www.w3.org/2001/XMLSchema#string